$11 Billion is the total value of Baker Brothers Advisors's 134 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 15.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Buy | Seattle Genetics, Inc. | $2,381,857,000 | +36.3% | 44,100,294 | +2.0% | 21.61% | +18.0% |
| INCY | Buy | Incyte Corporation | $2,215,711,000 | +17.9% | 23,498,898 | +0.0% | 20.11% | +2.0% |
| ABBV | Sell | AbbVie Inc. | $904,636,000 | +1.7% | 14,343,358 | -0.2% | 8.21% | -12.0% |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $821,327,000 | +3.2% | 25,819,768 | +5.3% | 7.45% | -10.7% |
| ALXN | Alexion Pharmaceuticals, Inc. | $801,815,000 | +5.0% | 6,543,295 | 0.0% | 7.28% | -9.2% | |
| Incyte Corporation Notes 1.25% 11/15/2020 144Anote 1.25% 11/15/2020 | $531,244,000 | +13.7% | 274,500,000 | 0.0% | 4.82% | -1.6% | ||
| Incyte Corporation Notes 0.375% 11/15/2018 144Anote 0.375% 11/15/2018 | $491,344,000 | +13.8% | 259,000,000 | 0.0% | 4.46% | -1.5% | ||
| BMRN | BioMarin Pharmaceutical Inc. | $444,696,000 | +18.9% | 4,806,483 | 0.0% | 4.04% | +2.9% | |
| GHDX | Buy | Genomic Health, Inc. | $398,237,000 | +12.5% | 13,770,302 | +0.7% | 3.61% | -2.6% |
| DBVT | DBV Technologies S.A.sponsored adr | $200,162,000 | +11.4% | 5,509,560 | 0.0% | 1.82% | -3.6% | |
| AQXP | Buy | Aquinox Pharmaceuticals, Inc. | $140,762,000 | +174.3% | 10,536,092 | +35.9% | 1.28% | +137.4% |
| BioMarin Pharmaceutical Inc. Notes 1.875% 4/23/2017note 1.875% 4/23/2017 | $101,405,000 | +19.4% | 22,379,000 | 0.0% | 0.92% | +3.4% | ||
| BLCM | Bellicum Pharmaceuticals, Inc. | $96,826,000 | +53.5% | 4,865,647 | 0.0% | 0.88% | +33.0% | |
| CERS | Sell | Cerus Corporation | $81,061,000 | -4.2% | 13,053,275 | -3.7% | 0.74% | -17.0% |
| ONCE | Spark Therapeutics, Inc. | $79,180,000 | +17.5% | 1,318,341 | 0.0% | 0.72% | +1.7% | |
| ACOR | Acorda Therapeutics, Inc. | $76,443,000 | -18.1% | 3,661,082 | 0.0% | 0.69% | -29.1% | |
| Clovis Oncology, Inc. 2.5% 9/15/2021note 2.5% 9/15/2021 | $69,135,000 | +34.7% | 72,758,000 | 0.0% | 0.63% | +16.5% | ||
| AMRN | Buy | Amarin Corporation plcsponsored adr new | $65,811,000 | +3699.7% | 20,630,477 | +2472.8% | 0.60% | +3216.7% |
| EXEL | Buy | Exelixis, Inc. | $63,048,000 | +212.9% | 4,929,494 | +91.1% | 0.57% | +171.1% |
| Acorda Therapeutics, Inc. Notes 1.75% 6/15/2021note 1.75% 6/15/2021 | $62,830,000 | -6.7% | 77,083,000 | 0.0% | 0.57% | -19.3% | ||
| BGNE | BeiGene, Ltd.sponsored adr | $58,930,000 | +3.4% | 1,912,680 | 0.0% | 0.54% | -10.5% | |
| NVTA | Invitae Corporation | $57,422,000 | +18.5% | 6,554,967 | 0.0% | 0.52% | +2.6% | |
| HRTX | Heron Therapeutics, Inc. | $49,230,000 | -4.5% | 2,857,250 | 0.0% | 0.45% | -17.4% | |
| BCRX | Sell | BioCryst Pharmaceuticals, Inc. | $48,351,000 | +13.4% | 10,963,944 | -27.0% | 0.44% | -1.8% |
| NBIX | Neurocrine Biosciences, Inc. | $45,344,000 | +11.4% | 895,422 | 0.0% | 0.41% | -3.7% | |
| AAAP | Buy | Advanced Accelerator Applications S.A.sponsored adr | $39,194,000 | +55.6% | 1,029,247 | +23.5% | 0.36% | +34.8% |
| VSAR | Sell | Versartis, Inc. | $26,145,000 | -13.2% | 2,134,247 | -21.6% | 0.24% | -25.0% |
| PGNX | Sell | Progenics Pharmaceuticals, Inc. | $23,110,000 | +37.9% | 3,650,808 | -8.0% | 0.21% | +19.3% |
| FOMX | Buy | Foamix Pharmaceuticals Ltd. | $22,842,000 | +60.5% | 2,466,702 | +10.0% | 0.21% | +38.9% |
| ARRY | Sell | Array BioPharma Inc. | $22,347,000 | +45.6% | 3,310,666 | -23.2% | 0.20% | +26.1% |
| XNCR | Xencor, Inc. | $21,357,000 | +29.0% | 872,072 | 0.0% | 0.19% | +11.5% | |
| HALO | Sell | Halozyme Therapeutics, Inc. | $20,911,000 | +31.8% | 1,731,057 | -5.8% | 0.19% | +14.5% |
| ACHN | Achillion Pharmaceuticals, Inc. | $20,052,000 | +3.8% | 2,475,515 | 0.0% | 0.18% | -9.9% | |
| BLUE | bluebird bio, Inc. | $19,923,000 | +56.6% | 293,943 | 0.0% | 0.18% | +36.1% | |
| MRUS | Buy | Merus N.V. | $19,430,000 | +116.6% | 1,160,014 | +3.3% | 0.18% | +87.2% |
| SGMO | Sangamo BioSciences, Inc. | $18,779,000 | -20.0% | 4,055,876 | 0.0% | 0.17% | -30.9% | |
| NTLA | Intellia Therapeutics, Inc. | $18,077,000 | -20.3% | 1,062,120 | 0.0% | 0.16% | -31.1% | |
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $17,956,000 | +67.6% | 7,014,015 | +0.2% | 0.16% | +45.5% |
| DSCI | Derma Sciences, Inc. | $17,524,000 | +18.5% | 3,752,390 | 0.0% | 0.16% | +2.6% | |
| Aegerion Pharmaceuticals, Inc. Notes 2.0% 8/15/2019note 2.0% 8/15/2019 | $17,432,000 | +17.5% | 26,517,000 | 0.0% | 0.16% | +1.3% | ||
| GLPG | Galapagos NVsponsored adr | $16,805,000 | +16.6% | 259,894 | 0.0% | 0.15% | +0.7% | |
| TGTX | TG Therapeutics, Inc. | $15,511,000 | +27.7% | 2,003,991 | 0.0% | 0.14% | +11.0% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $14,985,000 | +51.5% | 745,521 | 0.0% | 0.14% | +30.8% | |
| MRTX | Mirati Therapeutics, Inc. | $14,999,000 | +21.1% | 2,269,198 | 0.0% | 0.14% | +4.6% | |
| BioMarin Pharmaceutical Inc. Notes 0.75% 10/15/2018note 0.75% 10/15/2018 | $14,630,000 | +7.8% | 12,228,000 | 0.0% | 0.13% | -6.3% | ||
| ARWR | Buy | Arrowhead Pharmaceuticals, Inc. | $13,649,000 | +154.1% | 1,856,967 | +83.9% | 0.12% | +121.4% |
| VTAE | Vitae Pharmaceuticals, Inc. | $13,339,000 | +93.9% | 637,597 | 0.0% | 0.12% | +68.1% | |
| ALKS | Alkermes plc | $11,769,000 | +8.8% | 250,251 | 0.0% | 0.11% | -5.3% | |
| ZGNX | Zogenix, Inc. | $11,430,000 | +42.0% | 1,000,000 | 0.0% | 0.10% | +23.8% | |
| AERI | Aerie Pharmaceuticals, Inc. | $11,298,000 | +114.4% | 299,356 | 0.0% | 0.10% | +87.3% | |
| DERM | Dermira, Inc. | $11,040,000 | +15.6% | 326,428 | 0.0% | 0.10% | 0.0% | |
| AGIO | Agios Pharmaceuticals, Inc. | $10,982,000 | +26.1% | 207,915 | 0.0% | 0.10% | +9.9% | |
| MGNX | MacroGenics, Inc. | $10,878,000 | +10.8% | 363,676 | 0.0% | 0.10% | -3.9% | |
| AIMT | Aimmune Therapeutics, Inc. | $10,109,000 | +38.6% | 673,908 | 0.0% | 0.09% | +21.1% | |
| CFRX | New | ContraFect Corporation | $10,034,000 | – | 4,045,876 | +100.0% | 0.09% | – |
| DMTX | Dimension Therapeutics, Inc. | $10,003,000 | +33.2% | 1,251,881 | 0.0% | 0.09% | +15.2% | |
| SAGE | Sell | Sage Therapeutics, Inc. | $9,594,000 | +42.1% | 208,328 | -7.0% | 0.09% | +22.5% |
| ITCI | Intra-Cellular Therapies, Inc. | $9,284,000 | -60.7% | 609,166 | 0.0% | 0.08% | -66.1% | |
| IMGN | ImmunoGen, Inc. | $8,081,000 | -13.0% | 3,015,353 | 0.0% | 0.07% | -24.7% | |
| LGND | Ligand Pharmaceuticals Incorporated | $7,490,000 | -14.4% | 73,386 | 0.0% | 0.07% | -26.1% | |
| ALDR | Alder BioPharmaceuticals, Inc. | $7,122,000 | +31.2% | 217,328 | 0.0% | 0.06% | +14.0% | |
| RARE | Sell | Ultragenyx Pharmaceutical Inc. | $7,094,000 | +30.8% | 100,000 | -9.8% | 0.06% | +12.3% |
| New | Inotek Pharmaceuticals Corporation Notes 5.75% 8/1/2021note 5.75% 8/1/2021 | $6,708,000 | – | 5,000,000 | +100.0% | 0.06% | – | |
| Buy | Trillium Therapeutics Inc. | $6,120,000 | +221.8% | 413,697 | +95.3% | 0.06% | +180.0% | |
| INSM | Sell | Insmed Incorporated | $5,808,000 | -60.7% | 400,000 | -73.3% | 0.05% | -65.8% |
| ADHD | Alcobra Ltd. | $5,771,000 | -45.0% | 2,336,359 | 0.0% | 0.05% | -52.7% | |
| PRQR | Sell | ProQR Therapeutics N.V. | $5,739,000 | -3.9% | 860,464 | -30.3% | 0.05% | -17.5% |
| NeuroDerm Ltd. | $5,639,000 | +13.8% | 305,000 | 0.0% | 0.05% | -1.9% | ||
| CPRX | Sell | Catalyst Pharmaceuticals, Inc. | $5,561,000 | +52.9% | 5,102,153 | -0.4% | 0.05% | +31.6% |
| MDGN | Medgenics, Inc. | $4,905,000 | +0.4% | 880,539 | 0.0% | 0.04% | -11.8% | |
| NTRA | Natera, Inc. | $5,000,000 | -7.9% | 450,000 | 0.0% | 0.04% | -21.1% | |
| AKTX | Akari Therapeutics plcsponsored adr | $4,229,000 | -36.9% | 496,901 | 0.0% | 0.04% | -45.7% | |
| LOXO | Loxo Oncology, Inc. | $3,606,000 | +12.9% | 137,735 | 0.0% | 0.03% | 0.0% | |
| NERV | Sell | Minerva Neurosciences, Inc. | $3,653,000 | -29.6% | 258,805 | -49.1% | 0.03% | -38.9% |
| RXDX | Ignyta, Inc. | $3,592,000 | +16.1% | 571,000 | 0.0% | 0.03% | +3.1% | |
| STML | Stemline Therapeutics, Inc. | $3,612,000 | +60.0% | 333,497 | 0.0% | 0.03% | +37.5% | |
| Array BioPharma Inc. Notes 3.0% 6/1/2020note 3.0% 6/1/2020 | $3,561,000 | +40.0% | 3,000,000 | 0.0% | 0.03% | +18.5% | ||
| CNCE | Sell | Concert Pharmaceuticals, Inc. | $3,205,000 | -39.3% | 316,976 | -32.6% | 0.03% | -47.3% |
| SNSS | New | Sunesis Pharmaceuticals, Inc. | $3,241,000 | – | 741,665 | +100.0% | 0.03% | – |
| TRVN | Trevena, Inc. | $3,038,000 | +7.2% | 450,000 | 0.0% | 0.03% | -6.7% | |
| SYRS | Syros Pharmaceuticals, Inc. | $2,836,000 | -23.6% | 204,465 | 0.0% | 0.03% | -33.3% | |
| ADMS | Adamas Pharmaceuticals, Inc. | $2,833,000 | +8.4% | 172,630 | 0.0% | 0.03% | -3.7% | |
| NVIV | InVivo Therapeutics Holdings Corp. | $2,720,000 | +17.6% | 400,000 | 0.0% | 0.02% | +4.2% | |
| GLYC | GlycoMimetics, Inc. | $2,726,000 | -1.7% | 381,235 | 0.0% | 0.02% | -13.8% | |
| PRTO | Proteon Therapeutics, Inc. | $2,786,000 | +16.2% | 298,591 | 0.0% | 0.02% | 0.0% | |
| ECYT | Sell | Endocyte, Inc. | $2,685,000 | -26.0% | 868,983 | -23.1% | 0.02% | -36.8% |
| AGLE | Aeglea BioTherapeutics, Inc. | $2,591,000 | +31.9% | 404,230 | 0.0% | 0.02% | +14.3% | |
| SELB | Selecta Biosciences, Inc. | $2,550,000 | +1.8% | 178,950 | 0.0% | 0.02% | -11.5% | |
| OSIR | Osiris Therapeutics, Inc. | $2,476,000 | -2.6% | 499,193 | 0.0% | 0.02% | -18.5% | |
| JUNO | Juno Therapeutics, Inc. | $2,401,000 | -21.9% | 80,000 | 0.0% | 0.02% | -31.2% | |
| NBRV | Nabriva Therapeutics AGsponsored adr | $2,468,000 | -6.0% | 350,000 | 0.0% | 0.02% | -21.4% | |
| Protalix BioTherapeutics, Inc. Notes 4.5% 9/15/18note 4.5% 9/15/2018 | $2,294,000 | -0.3% | 3,423,000 | 0.0% | 0.02% | -12.5% | ||
| EPZM | Epizyme, Inc. | $2,288,000 | -3.9% | 232,481 | 0.0% | 0.02% | -16.0% | |
| KPTI | Karyopharm Therapeutics Inc. | $2,111,000 | +45.0% | 216,990 | 0.0% | 0.02% | +26.7% | |
| IONS | Ionis Pharmaceuticals, Inc. | $2,094,000 | +57.3% | 57,140 | 0.0% | 0.02% | +35.7% | |
| ENTA | Enanta Pharmaceuticals, Inc. | $2,005,000 | +20.6% | 75,357 | 0.0% | 0.02% | +5.9% | |
| MDWD | MediWound Ltd. | $1,740,000 | -2.4% | 226,000 | 0.0% | 0.02% | -15.8% | |
| QURE | uniQure N.V. | $1,760,000 | +3.8% | 230,000 | 0.0% | 0.02% | -11.1% | |
| ASMB | Assembly Biosciences, Inc. | $1,803,000 | +29.9% | 250,000 | 0.0% | 0.02% | +6.7% | |
| SCYX | SCYNEXIS, Inc. | $1,810,000 | +78.3% | 467,600 | 0.0% | 0.02% | +45.5% | |
| MYOK | New | MyoKardia, Inc. | $1,634,000 | – | 100,000 | +100.0% | 0.02% | – |
| OPHT | Ophthotech Corporation | $1,644,000 | -9.6% | 35,649 | 0.0% | 0.02% | -21.1% | |
| MCRB | Seres Therapeutics, Inc. | $1,536,000 | -57.7% | 125,000 | 0.0% | 0.01% | -63.2% | |
| PTN | Palatin Technologies, Inc. | $1,289,000 | +42.4% | 2,050,000 | 0.0% | 0.01% | +33.3% | |
| CLLS | Cellectis S.A.sponsored ads | $1,204,000 | -9.5% | 50,000 | 0.0% | 0.01% | -21.4% | |
| AFMD | Affimed N.V. | $1,112,000 | +12.1% | 400,000 | 0.0% | 0.01% | 0.0% | |
| IMDZ | Immune Design Corp. | $1,129,000 | -7.1% | 148,937 | 0.0% | 0.01% | -23.1% | |
| FLGT | New | Fulgent Genetics, Inc. | $1,153,000 | – | 125,000 | +100.0% | 0.01% | – |
| ALDX | Aldeyra Therapeutics, Inc. | $1,110,000 | +37.4% | 142,000 | 0.0% | 0.01% | +25.0% | |
| CLCD | New | CoLucid Pharmaceuticals, Inc. | $1,156,000 | – | 30,310 | +100.0% | 0.01% | – |
| TENX | Tenax Therapeutics, Inc. | $972,000 | -9.6% | 420,000 | 0.0% | 0.01% | -18.2% | |
| FPRX | Five Prime Therapeutics, Inc. | $1,010,000 | +26.9% | 19,247 | 0.0% | 0.01% | +12.5% | |
| MSTX | Buy | Mast Therapeutics, Inc. | $944,000 | -48.1% | 8,584,051 | +121.9% | 0.01% | -52.6% |
| XLRN | Acceleron Pharma Inc. | $1,041,000 | +6.6% | 28,765 | 0.0% | 0.01% | -10.0% | |
| INFI | New | Infinity Pharmaceuticals, Inc. | $905,000 | – | 580,400 | +100.0% | 0.01% | – |
| New | Aptose Biosciences Inc. | $909,000 | – | 404,211 | +100.0% | 0.01% | – | |
| ALNY | Alnylam Pharmaceuticals, Inc. | $769,000 | +22.3% | 11,340 | 0.0% | 0.01% | 0.0% | |
| DVAX | Dynavax Technologies Corporation | $787,000 | -28.1% | 75,000 | 0.0% | 0.01% | -36.4% | |
| MDGL | New | Madrigal Pharmaceuticals, Inc. | $732,000 | – | 57,762 | +100.0% | 0.01% | – |
| ABEO | New | Abeona Therapeutics Inc. | $610,000 | – | 101,680 | +100.0% | 0.01% | – |
| ABUS | Arbutus Biopharma Corporation | $621,000 | -1.1% | 180,582 | 0.0% | 0.01% | -14.3% | |
| RTTR | Ritter Pharmaceuticals, Inc. | $672,000 | +9.8% | 400,000 | 0.0% | 0.01% | 0.0% | |
| WINT | Windtree Therapeutics, Inc. | $653,000 | +32.7% | 254,973 | 0.0% | 0.01% | +20.0% | |
| CMRX | Chimerix, Inc. | $638,000 | +40.8% | 115,216 | 0.0% | 0.01% | +20.0% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $705,000 | -13.5% | 100,000 | 0.0% | 0.01% | -33.3% | |
| BDSI | BioDelivery Sciences International, Inc. | $567,000 | +14.3% | 210,021 | 0.0% | 0.01% | 0.0% | |
| CYTR | CytRx Corporation | $388,000 | -73.6% | 659,995 | 0.0% | 0.00% | -73.3% | |
| AKAOQ | Achaogen, Inc. | $479,000 | +26.4% | 100,000 | 0.0% | 0.00% | 0.0% | |
| FMI | Foundation Medicine, Inc. | $488,000 | +25.1% | 20,892 | 0.0% | 0.00% | 0.0% | |
| CCXI | ChemoCentryx, Inc. | $296,000 | +34.5% | 49,064 | 0.0% | 0.00% | +50.0% | |
| LJPC | La Jolla Pharmaceutical Company | $327,000 | +48.6% | 13,746 | 0.0% | 0.00% | +50.0% | |
| DNAI | ProNAi Therapeutics, Inc. | $364,000 | -8.5% | 200,000 | 0.0% | 0.00% | -25.0% | |
| CYCCP | Cyclacel Pharmaceuticals, Inc.pfd conv ex 6% | $90,000 | +8.4% | 13,253 | 0.0% | 0.00% | 0.0% | |
| BTXWS | BioTime, Inc.*w exp 10/1/201 | $17,000 | +88.9% | 20,084 | 0.0% | 0.00% | – | |
| SNTA | Exit | Synta Pharmaceuticals Corp. | $0 | – | -2,021,728 | -100.0% | -0.01% | – |
| GWPH | Exit | GW Pharmaceuticals plcads | $0 | – | -15,000 | -100.0% | -0.01% | – |
| AUPH | Exit | Aurinia Pharmaceuticals Inc. | $0 | – | -711,499 | -100.0% | -0.02% | – |
| SNSS | Exit | Sunesis Pharmaceuticals, Inc. | $0 | – | -4,450,000 | -100.0% | -0.03% | – |
| CRIS | Exit | Curis, Inc. | $0 | – | -1,999,303 | -100.0% | -0.03% | – |
| Exit | Corsicanto Ltd. 3.5% 1/15/2032note 3.5% 1/15/2032 | $0 | – | -15,000,000 | -100.0% | -0.16% | – | |
| NVAX | Exit | Novavax, Inc. | $0 | – | -2,379,254 | -100.0% | -0.18% | – |
| MDVN | Exit | Medivation, Inc. | $0 | – | -329,876 | -100.0% | -0.21% | – |
| XNPT | Exit | XenoPort, Inc. | $0 | – | -3,475,672 | -100.0% | -0.26% | – |
| Exit | Exelixis, Inc. Notes 4.25% 8/15/2019note 4.25% 8/15/2019 | $0 | – | -20,000,000 | -100.0% | -0.31% | – | |
| Exit | XenoPort, Inc. Notes 2.5% 2/1/2022note 2.5% 2/1/2022 | $0 | – | -100,000,000 | -100.0% | -1.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.